Cargando…

Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease

INTRODUCTION: The goal of this study was to assess the occurrence of steroid-associated adverse events (SAAE) in patients with primary proteinuric kidney disease. METHODS: The Kidney Research Network Registry consists of children and adults with primary proteinuric kidney disease. SAAEs of interest...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Gia J., Waldo, Anne, Paez-Cruz, Francisco, Gipson, Patrick E., Pesenson, Anne, Selewski, David T., Kamil, Elaine S., Massengill, Susan F., Lafayette, Richard A., Modes, Meg, Adler, Sharon G., Desmond, Hailey, Eikstadt, Richard, Attalla, Samara, Modi, Zubin J., Troost, Jonathan P., Gipson, Debbie S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933464/
https://www.ncbi.nlm.nih.gov/pubmed/31891002
http://dx.doi.org/10.1016/j.ekir.2019.08.019
_version_ 1783483220633845760
author Oh, Gia J.
Waldo, Anne
Paez-Cruz, Francisco
Gipson, Patrick E.
Pesenson, Anne
Selewski, David T.
Kamil, Elaine S.
Massengill, Susan F.
Lafayette, Richard A.
Modes, Meg
Adler, Sharon G.
Desmond, Hailey
Eikstadt, Richard
Attalla, Samara
Modi, Zubin J.
Troost, Jonathan P.
Gipson, Debbie S.
author_facet Oh, Gia J.
Waldo, Anne
Paez-Cruz, Francisco
Gipson, Patrick E.
Pesenson, Anne
Selewski, David T.
Kamil, Elaine S.
Massengill, Susan F.
Lafayette, Richard A.
Modes, Meg
Adler, Sharon G.
Desmond, Hailey
Eikstadt, Richard
Attalla, Samara
Modi, Zubin J.
Troost, Jonathan P.
Gipson, Debbie S.
author_sort Oh, Gia J.
collection PubMed
description INTRODUCTION: The goal of this study was to assess the occurrence of steroid-associated adverse events (SAAE) in patients with primary proteinuric kidney disease. METHODS: The Kidney Research Network Registry consists of children and adults with primary proteinuric kidney disease. SAAEs of interest were hypertension, hyperglycemia and diabetes, overweight and obesity, short stature, ophthalmologic complications, bone disorders, infections, and psychosis. Events were identified using International Classification of Diseases, Ninth Revision/Tenth Revision codes, blood pressures, growth parameters, laboratory values, and medications. Poisson generalized estimating equations tested the association between steroid onset and dose on SAAE risk. RESULTS: A total of 884 participants were included in the analysis; 534 (60%) were treated with steroids. Of these, 62% had at least one SAAE. The frequency of any SAAE after initiation of steroids was 293 per 1000 person-years. The most common SAAEs were hypertension (173.7 per 1000 person-years), diabetes (78.7 per 1000 person-years), obesity (66.8 per 1000 person-years), and infections (46.1 per 1000 person-years). After adjustment for demographics, duration of kidney disease, estimated glomerular filtration rate (eGFR), proteinuria, and other therapies, steroid exposure was associated with a 40% increase in risk of any SAAE (Relative risk [RR]: 1.4; 95% confidence interval [CI]: 1.3–1.6). A 1-mg/kg per day increase in steroid dose was associated with a 2.5-fold increase in risk of any SAAE. CONCLUSION: Most patients with primary proteinuric kidney disease treated with steroids experienced at least one SAAE. Steroid therapy increased risk of hypertension, diabetes, weight gain, short stature, fractures, and infections after adjusting for disease-related factors. This study highlights the importance of surveillance and management of SAAE and provides rationale for the development of steroid minimization protocols.
format Online
Article
Text
id pubmed-6933464
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69334642019-12-30 Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease Oh, Gia J. Waldo, Anne Paez-Cruz, Francisco Gipson, Patrick E. Pesenson, Anne Selewski, David T. Kamil, Elaine S. Massengill, Susan F. Lafayette, Richard A. Modes, Meg Adler, Sharon G. Desmond, Hailey Eikstadt, Richard Attalla, Samara Modi, Zubin J. Troost, Jonathan P. Gipson, Debbie S. Kidney Int Rep Clinical Research INTRODUCTION: The goal of this study was to assess the occurrence of steroid-associated adverse events (SAAE) in patients with primary proteinuric kidney disease. METHODS: The Kidney Research Network Registry consists of children and adults with primary proteinuric kidney disease. SAAEs of interest were hypertension, hyperglycemia and diabetes, overweight and obesity, short stature, ophthalmologic complications, bone disorders, infections, and psychosis. Events were identified using International Classification of Diseases, Ninth Revision/Tenth Revision codes, blood pressures, growth parameters, laboratory values, and medications. Poisson generalized estimating equations tested the association between steroid onset and dose on SAAE risk. RESULTS: A total of 884 participants were included in the analysis; 534 (60%) were treated with steroids. Of these, 62% had at least one SAAE. The frequency of any SAAE after initiation of steroids was 293 per 1000 person-years. The most common SAAEs were hypertension (173.7 per 1000 person-years), diabetes (78.7 per 1000 person-years), obesity (66.8 per 1000 person-years), and infections (46.1 per 1000 person-years). After adjustment for demographics, duration of kidney disease, estimated glomerular filtration rate (eGFR), proteinuria, and other therapies, steroid exposure was associated with a 40% increase in risk of any SAAE (Relative risk [RR]: 1.4; 95% confidence interval [CI]: 1.3–1.6). A 1-mg/kg per day increase in steroid dose was associated with a 2.5-fold increase in risk of any SAAE. CONCLUSION: Most patients with primary proteinuric kidney disease treated with steroids experienced at least one SAAE. Steroid therapy increased risk of hypertension, diabetes, weight gain, short stature, fractures, and infections after adjusting for disease-related factors. This study highlights the importance of surveillance and management of SAAE and provides rationale for the development of steroid minimization protocols. Elsevier 2019-09-09 /pmc/articles/PMC6933464/ /pubmed/31891002 http://dx.doi.org/10.1016/j.ekir.2019.08.019 Text en © 2019 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Oh, Gia J.
Waldo, Anne
Paez-Cruz, Francisco
Gipson, Patrick E.
Pesenson, Anne
Selewski, David T.
Kamil, Elaine S.
Massengill, Susan F.
Lafayette, Richard A.
Modes, Meg
Adler, Sharon G.
Desmond, Hailey
Eikstadt, Richard
Attalla, Samara
Modi, Zubin J.
Troost, Jonathan P.
Gipson, Debbie S.
Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
title Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
title_full Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
title_fullStr Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
title_full_unstemmed Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
title_short Steroid-Associated Side Effects in Patients With Primary Proteinuric Kidney Disease
title_sort steroid-associated side effects in patients with primary proteinuric kidney disease
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933464/
https://www.ncbi.nlm.nih.gov/pubmed/31891002
http://dx.doi.org/10.1016/j.ekir.2019.08.019
work_keys_str_mv AT ohgiaj steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT waldoanne steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT paezcruzfrancisco steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT gipsonpatricke steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT pesensonanne steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT selewskidavidt steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT kamilelaines steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT massengillsusanf steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT lafayettericharda steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT modesmeg steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT adlersharong steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT desmondhailey steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT eikstadtrichard steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT attallasamara steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT modizubinj steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT troostjonathanp steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease
AT gipsondebbies steroidassociatedsideeffectsinpatientswithprimaryproteinurickidneydisease